Skip to main content
All lobbying filings

MEDTRONIC, INC.

Lobbying for MEDTRONIC INC

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$1,610,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 14

Issues related to coverage and payment for breakthrough medical devices, including Ensuring Patient Access to Critical Breakthrough Products Act (S. 1717; H.R. 5343) and CMS Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway proposal Issues related to coverage and payment of AI and digital health technologies, including Health Tech Investment Act (S. 1399; H.R. 6197) Issues related to prior authorization, including CMMI WISeR Model Issues related to non-opioid pain therapies Issues related to transcatheter heart valve NCD Issues related to CY2027 OPPS/ASC Proposed Rule and multiple procedure reduction Issues related to CY2027 Physician Fee Schedule Proposed Rule and Modifier 25 payment reduction

Issues related to the taxation of multinational corporations corporations

Issues related to global supply chains including rare earth and critical minerals including S.3658 the Securing Essential and Critical U.S. Resources and Elements Minerals Act of 2026 Issues related to supply chain resiliency including memory chip shortages Issues related to data and the cloud including H.R. 2683/S. 3519, the Remote Access Security Act Issues related to tariffs Issues related to the renewal of USMCA Issues related to secondary tariff authority under PL 119-111, the Lindsey O. Graham Sanctioning Russia and Iran Act of 2026

Issues related to medical device electronic labeling, including H.R. 1539/S. 4519 - Medical Device Electronic Labeling Act Issues related to hypertension Issues related to the sterilization of medical devices Issues related to servicing and repair of medical devices, including related to H.R. 8800/S.4784, the National Defense Authorization Act of 2027 Issues related to artificial intelligence and other advanced software in health care Issues related to Parkinsons disease Issues related to epilepsy Issues related to overactive bladder and urinary incontinence Issues related to pelvic venous disorder (PeVD) Issues related to the medical supply chain

Issues related to cybersecurity, including reauthorization of the Cybersecurity Information Sharing Act of 2015

Issues related to anti-trust and competition

Issues related to intellectual property including S. 1553, the PREVAIL Act, S.1546, the Patent Eligibility Restoration Act of 2025, and S.708, the RESTORE Patent Rights Act of 2025 Issues related to Patent Trial and Appeal Board procedures

Monitoring Environmental, Social and Governance (ESG) issues Issues related to the sterilization of medical devices Issues related to the use of polyfluoroalkyl substances

Issues related to data privacy and data security, including H.R. 8413, the Securing and Establishing Uniform Rights and Enforcement over Data Act Issues related to artificial intelligence enabled medical devices and emerging technologies, including H.R. 9924, the FRONTIER Act Issues related to right to repair

Issues related to hypertension Issues related to procurement of healthcare technologies

Issues related to the National Defense Authorization Act for Fiscal Year 2027 including servicing and repair of medical devices and dividend and shareholder buyback policies

Issues related to hypertension, including FY27 MilCon/Veterans Appropriations Issues related to overactive bladder and urinary incontinence, including FY27 Labor/HHS Appropriations

Issues related to third party litigating funding

Issues related to the issuance of dividends, including provisions of H.R. 8800/S.4784, the National Defense Authorization Act of 2027

 Bills named in this filing 16
  • S. 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
  • H.R. 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
  • S. 1399
    Health Tech Investment Act
  • H.R. 6197
    Health Tech Investment Act
  • S. 3658
    SHIFT Act
  • H.R. 2683
    Remote Access Security Act
  • S. 3519
    Remote Access Security Act
  • H.R. 1539
    Medical Device Electronic Labeling Act
  • S. 4519
    Medical Device Electronic Labeling Act
  • H.R. 8800
    National Defense Authorization Act for Fiscal Year 2027
  • S. 4784
    National Defense Authorization Act for Fiscal Year 2027
  • S. 1553
    PREVAIL Act
  • S. 1546
    Patent Eligibility Restoration Act of 2025
  • S. 708
    RESTORE Patent Rights Act of 2025
  • H.R. 8413
    SECURE Data Act
  • H.R. 9924
    Local Input Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem